Search

Background: Advancement in cancer molecular diagnostics has paved the way for greater understanding of cancer biology, its heterogeneity, and its dynamics leading to development of personalised cancer care--targeted treatment tailored to the patient's personal tumour profile. Molecular profiling serves as a tool for diagnostic transformation for those refractory to standard conventional therapy with directed personalised treatment guided by tumour biology, thus maximising treatment potential for those likely to benefit, minimising the toxic effects of treatment, and improving patient outcomes. We aimed to describe the treatment outcome (based on RECIST) of patients who underwent treatment according to molecular profiling. Methods: A chart review of Filipino cancer patients who underwent molecular profiling was done, covering the period 2009-12. Age, gender, histologically proven cancer diagnosis, chemotherapeutic and biological treatment regimens, number of lines of treatment, and timing of molecular profiling were documented. Treatment outcomes based on RECIST, assessed by CT scan, were recorded after each regimen of at least three cycles or after a CT scan evaluation was deemed necessary by the clinician. Findings: Among nine patients whose treatment agents were documented to be "benefit" by molecular profiling, the following outcomes were noted: complete response (13%), partial response (63%), stable disease (13%) and progressive disease (13%). Clinical benefit ratio was 88% in this group. Among patients whose treatment agents were determined to be with "benefit" and "no benefit" agents, partial response, stable disease, and progressive disease were reported in 17%, 67% and 17%, respectively. Clinical benefit ratio was 83% in this group. Among patients whose treatment agents were of "no benefit", 100% had progressive disease. [ABSTRACT FROM AUTHOR]